Bionor's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x and Vacc-C5 in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor retains full ownership rights to the HIV immunotherapy Vacc-4x and Vacc-C5, i.e., the upside potential from partnering or licensing remains with the Company.
View Top Employees from Bionor Holding AS| Website | http://www.bionorholding.com |
| Revenue | $2 million |
| Funding | $11.6 million |
| Employees | 6 (4 on RocketReach) |
| Founded | 1986 |
| Address | Kronprinsesse Märthas Plass 1 Vika, Oslo, Oslo 0116, NO |
| Phone | (472) 301-0960 |
| Technologies |
JavaScript,
HTML,
PHP
+9 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Healthcare, HIV, Peptide-based vaccines against viral diseases, Drug Manufacturing & Research |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 2834 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Bionor Holding AS employee's phone or email?
Bionor Holding AS Questions
The Bionor Holding AS annual revenue was $2 million in 2024.
4 people are employed at Bionor Holding AS.
Bionor Holding AS is based in Oslo, Oslo.
The NAICS codes for Bionor Holding AS are [325, 3254, 32, 32541].
The SIC codes for Bionor Holding AS are [283, 28, 2834].
Top Bionor Holding AS Employees
Related Companies
